Balance Sheet
Cash Flow Statement
AmortizationAmortization of GoodwillAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Legend Biotech (LEGN) Asset Writedowns and Impairment (2020 - 2025)

Historic Asset Writedowns and Impairment for Legend Biotech (LEGN) over the last 5 years, with Q3 2025 value amounting to $865000.0.

  • Legend Biotech's Asset Writedowns and Impairment rose 11464.02% to $865000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.6 million, marking a year-over-year decrease of 14737.33%. This contributed to the annual value of $280.2 million for FY2020, which is N/A changed from last year.
  • Latest data reveals that Legend Biotech reported Asset Writedowns and Impairment of $865000.0 as of Q3 2025, which was up 11464.02% from -$1.1 million recorded in Q2 2025.
  • Over the past 5 years, Legend Biotech's Asset Writedowns and Impairment peaked at $339.9 million during Q2 2021, and registered a low of -$3.8 million during Q1 2025.
  • Its 4-year average for Asset Writedowns and Impairment is $51.8 million, with a median of $767000.0 in 2023.
  • In the last 5 years, Legend Biotech's Asset Writedowns and Impairment skyrocketed by 196548.67% in 2024 and then plummeted by 31616.39% in 2025.
  • Over the past 4 years, Legend Biotech's Asset Writedowns and Impairment (Quarter) stood at $225.8 million in 2021, then crashed by 99.66% to $767000.0 in 2023, then crashed by 47.46% to $403000.0 in 2024, then skyrocketed by 114.64% to $865000.0 in 2025.
  • Its Asset Writedowns and Impairment stands at $865000.0 for Q3 2025, versus -$1.1 million for Q2 2025 and -$3.8 million for Q1 2025.